复方斑蝥胶囊联合新辅助化疗对HER2阴性乳腺癌的疗效及其对Ki67、ER和PR表达的影响  

Effect of compound mylabris capsules combined with neoadjuvant on efficacy and expression of Ki67,ER,PR in patients with HER2-negative breast carcinoma

作　　者：李莉[1] 纳智明[1] 王建军[1] 

机构地区：[1]云南省第一人民医院乳腺甲状腺肿瘤外科,云南昆明650032

出　　处：《中国生化药物杂志》2015年第11期103-106,共4页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨复方斑蝥胶囊联合新辅助化疗对人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阴性乳腺癌的疗效以及对细胞核相关抗原Ki67、雌激素受体(estrogen receptor,ER)和孕激素受体(progesterone receptor,PR)水平的影响。方法选择云南省第一人民医院乳腺甲状腺肿瘤外科确诊的HER2阴性乳腺癌患者共81例,根据随机数字表法分为治疗组41例和对照组40例;对照组采取新辅助化疗方案(AC序贯T);首先给予环磷酰胺(cyclophosvnamide,CTX)600 mg/m2+阿霉素(Adriamycin,Ad)60 mg/m2,采用3周方案;多西他赛(docetaxel,DOC)在CTX和Ad结束后的下一疗程开始,100 mg/m2,静脉滴注1 h,1周期/3周,1次/周期,共6周。治疗组在对照组基础上口服复方斑蝥胶囊,于化疗前1 d开始,3粒/次,2次/天,7次/周期,化疗结束后继续干预1周。比较2组中医(TCM)症状评分、临床疗效及血液流变学指标水平;检测2组Ki67、ER及PR水平。结果治疗组近期临床总有效率为56.10%,明显高于对照组的30.00%(P<0.05);化疗结束时及化疗后1周,治疗组患者TCM症状评分、血浆黏度及全血高切、中切、低切黏度均明显低于对照组(P<0.05);新辅助化疗前和新辅助化疗后,治疗组Ki67水平明显低于对照组,ER和PR水平均明显高于对照组(P<0.05)。结论复方斑蝥胶囊联合新辅助化疗可明显降低HER2阴性乳腺癌患者的TCM症状评分,改善血液粘度,提高临床疗效,抑制Ki67表达水平同时上调ER和PR水平。Objective To investigate effect of compound mylabris capsules combined with neoadjuvant on efficacy and expression of Ki67,ER,PR in patients with HER2-negative breast carcinoma. Methods Eighty-one HER2 negative-breast cancer patients from the hospital were randomly divided into treatment group（ 41cases） and control group（ 40 cases） by random number table method. Control group was treated with three weeks of neoadjuvant chemotherapy,firstly given with cyclophosphamide（ CTX） 600 mg / m2＋ adriamycin amycin（ Ad） 60 mg / m2,and then next course with docetaxel（ DOC）100 mg / m2,intravenous drip for 1 h,one period per three weeks,one times per week,and for 6 periods. Patients in treatment group were additionally given with compound mylabris capsules from one day before chemotherapy,three particles per time,two times per day,seven times per period,and for another one week after chemotherapy. Score of traditional Chinese medicine（ TCM） symptoms,clinical efficacy,and levels of hemorheology indexs were compared. Serum levels of Ki67,ER,and PR were detected between both groups. Results Total efficacy of treatment group was recently 56. 10%,which was superior to control group 30. 00%（ P〈0. 05）. AT the ending of chemotherapy and 1 weeks after chemotherapy,TCM score,plasma viscosity,and high,middle and low shear of whole blood were obviously lower than control group（ P〈0. 05）. Serum level of Ki67 in treatment group was lower,while ER and PR were higher than control group at the ending of chemotherapy and 1 weeks after chemotherapy with statistically significant difference（ P〈0. 05）. Conclusion Compound mylabris capsules combined with neoadjuvant chemotherapy in treating breast carcinoma with HER2 negative can decrease TCM symptoms,improve blood viscosity and clinical efficacy,and inhibit expression of Ki67 and up-regualte ER and PR levels.

关 键 词：复方斑蝥胶囊 新辅助化疗 人表皮生长因子受体2 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]